Nitrosamine Impurities Affecting Drug-Drug Interaction Studies – Learn More

Industry Leading Nicotine Researcher Joins Celerion Research Team

Industry Leading Nicotine Researcher Joins Celerion Research Team

Dr. Ian Fearon further enhances Celerion’s renowned capabilities

Lincoln, NE (January 23, 2018) – Celerion, the leader in Nicotine Clinical Research Services, is pleased to announce that Dr. Ian M. Fearon has joined Celerion’s industry leading Nicotine Research Team.

Prior to joining Celerion, Dr. Fearon was Principal Scientist and Head of Clinical Research at British American Nicotine R&D where he was responsible for defining the strategy for developing and implementing clinical research programs in support of regulatory submissions and product launches.  During his long career at British American Nicotine, Dr. Fearon published extensively in prestigious, peer reviewed journals such as International Journal of Clinical Trials, BMC Public Health, American Journal of Health Behavior, Regulatory Toxicology & Pharmacology and many others.

Celerion’s capabilities support all elements of nicotine research from regulatory consulting to clinical development, bioanalysis, data analysis and reporting. Dr. Fearon will be joining the elite Celerion scientific team which includes Dr. Donald Graff, Director Nicotine Research, and Kirk Newland, Technical Director Nicotine Science.  Over the past 17 years, the Celerion nicotine team has designed, consulted on, or analyzed data for more than 100 clinical studies, including large multi-site trials that have contributed to the development of potential reduced harm nicotine products. In addition to our two purpose-built facilities, strategically located in the US and EU, Celerion has cultivated a network of U.S. sites equipped to handle the unique requirements specific to larger nicotine product evaluations. Celerion’s world leading bioanalytical laboratory offers extensive expertise in the assessment of nicotine constituents, having analyzed over 500,000 samples in the past 3 years. Celerion has made significant investments in the area of nicotine harm reduction research, including a patented approach for testing e-cigarettes using stable isotope solvents.

Celerion, a leader in clinical research services, is a global company with over 1,000 employees worldwide. Our unique combination of medical expertise, clinical operations experience and scientific excellence provides our customers with the confidence to make fast, accurate decisions about their product development path within the clinical research process.  Our founding mission is to help our clients get their products to market quickly, impacting public health needs around the world. For more information please visit

Leslie C. Poli
Senior Director
M: +1 919 324 4397